Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genedrive ( (GB:GDR) ) has shared an update.
Genedrive plc announced significant share acquisitions by its top executives, indicating strong internal confidence in the company’s future. With key personnel, including the CEO and CFO, increasing their holdings, this move could reinforce market confidence and support Genedrive’s strategic growth plans in the pharmacogenetic testing sector.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that specializes in developing and commercializing a cost-effective, rapid, and user-friendly point-of-need pharmacogenetic platform. This platform aids clinicians in identifying key genetic information to make informed decisions about appropriate medication or dosages, particularly in emergency care. Notably, Genedrive’s flagship products, the MT-RNR1 ID Kit and CYP2C19 ID Kit, have been developed in collaboration with NHS partners and are recommended by NICE for use in the UK NHS.
YTD Price Performance: -67.69%
Average Trading Volume: 9,204,737
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £11.41M
See more insights into GDR stock on TipRanks’ Stock Analysis page.
